Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study
Alexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour, Guillermo Montalban‐Bravo, Maro Ohanian, Kelly S. Chien, Tapan M. Kadia, Koichi Takahashi, Lucia Masárová, Nicholas J. Short, Yesid Alvarado, Musa Yılmaz, Farhad Ravandi, Michael Andreeff, Rashmi Kanagal‐Shamanna, Irene Gañán‐Gómez, Simona Colla, Wei Qiao, Xuelin Huang, Deborah McCue, Bailey Mirabella, Hagop M. Kantarjian, Guillermo Garcia‐Manero
Topics & Concepts
VenetoclaxAzacitidineTolerabilityMedicineMyelodysplastic syndromesHypomethylating agentDecitabineChronic myelomonocytic leukemiaInternal medicineNeutropeniaOncologyLenalidomideInternational Prognostic Scoring SystemPhases of clinical researchClinical trialLeukemiaAdverse effectBone marrowChemotherapyChronic lymphocytic leukemiaDexamethasoneDNA methylationGene expressionChemistryBiochemistryGeneAcute Myeloid Leukemia ResearchBlood disorders and treatmentsMyeloproliferative Neoplasms: Diagnosis and Treatment